Lilia (Chlormadinone Acetate, Ethinylestradiol)

The ethinylestradiol component provides estrogenic activity that stabilises the endometrial lining, while chlormadinone acetate acts as a progestogen. Together they suppress the mid‑cycle surge of luteinising hormone (LH) and follicle‑stimulating hormone (FSH), inhibiting ovulation and inducing cervical mucus changes that impede sperm penetration.

The specific dosing regimen for Lilia is determined by the prescribing clinician based on the product’s labeling and the patient’s individual needs. Typically, combined oral contraceptives are taken once daily for 21 days followed by a hormone‑free interval, but the exact schedule should be confirmed with a qualified health‑care professional.

Lilia is classified as pregnancy category X, meaning it must not be used during pregnancy because it can cause fetal harm. It is also not recommended for breastfeeding women, as hormonal contraceptives may affect milk production and expose the infant to estrogen and progestogen. Alternative non‑hormonal methods should be considered in these situations.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity of Lilia. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any required temperature control) and necessary import documentation.

Lilia contains chlormadinone acetate as the progestogenic component, which is less commonly used than levonorgestrel or desogestrel in many other pills. This may offer a different side‑effect profile, such as lower androgenic activity, but overall efficacy in preventing pregnancy is comparable to other FDA‑approved combined oral contraceptives when taken correctly.

Lilia tablets should be stored at ambient temperature, below 25 °C (77 °F). Keep them in the original blister pack or container, protect from moisture, heat and direct sunlight, and ensure they are out of reach of children. Do not store in the bathroom or near a kitchen sink where humidity is high.

Lilia is taken orally, usually as a tablet taken at the same time each day. The typical regimen involves a 21‑day active tablet sequence followed by a 7‑day pill‑free interval, during which withdrawal bleeding occurs. Patients should swallow the tablet whole with water and should not split or crush it.

The most serious risks include venous thromboembolism (deep‑vein thrombosis or pulmonary embolism), arterial thrombosis leading to stroke or myocardial infarction, and severe hypertension. Women with a history of clotting disorders, smoking over age 35, or certain cardiovascular conditions should avoid Lilia and seek alternative contraception.

Lilia is contraindicated in women who are pregnant or suspect they may be pregnant, those with known or suspected estrogen‑dependent tumors, active or history of thromboembolic disease, uncontrolled hypertension, severe liver disease, or who are smokers aged 35 years or older. It should also be avoided in individuals with known hypersensitivity to either chlormadinone acetate or ethinylestradiol.